SNDX News and Press, Syndax Pharmaceuticals Inc. From 11/03/23

Syndax Pharmaceuticals Inc. (SNDX) is expected to report $-0.8 for Q3 2023

2023-11-02 21:26:05 ET Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Results Conference Call November 02, 2023 04:30 PM ET Company Participants Sharon Klahre - Head of Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President and Head of...

2023-11-02 16:45:43 ET More on Syndax Pharmaceuticals Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023 Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript BofA sta...

Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update PR Newswire –  NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR  – –  mNPM1 final efficacy da...

Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting PR Newswire – Additional data from pivotal AUGMENT-101 trial in R/R KMT2Ar acute leukemia further...

Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting PR Newswire –  Results support axatilimab's promising safety and efficacy profile, and rein...

Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023 PR Newswire WALTHAM, Mass. , Oct. 26, 2023 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developin...

2023-10-25 16:02:55 ET More on Syndax Pharmaceuticals Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023 Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript Syndax i...

Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program PR Newswire – Solidifies first-to-market potential for revumenib – – High unmet need in relapsed o...

2023-10-13 14:52:22 ET Summary Syndax Pharmaceuticals, Inc. reported positive results from its phase 1/2 trial using revumenib to treat relapsed/refractory leukemia patients. The trial met its primary endpoint with a complete remission rate of 23%, significantly higher than the cu...